Please Wait.....
Report
U.S. Point Of Care Testing Market
Market Report I 2025-09-01 I 350 Pages I Data Bridge Market Research
The U.S. point of care testing market is expected to reach USD 28.23 billion by 2032 from USD 13.50 billion in 2024, growing with a substantial CAGR of 9.7% in the forecast period of 2025 to 2032.
Market Segmentation:
U.S. Point of Care Testing Market, By Product/Disease (Sexually Transmitted Disease (STD), Hepatitis, Respiratory Infections, Gastroenteric Infections, Bloodstream Infections (BSI), Blood Yeast Infections and Others), Method/Technology (Nucleic Acid Amplification Tests (NAAT), Loop-Mediated Isothermal Amplification (LAMP), Microfluidics/ Lab-On-a-Chip and Others), Panel Type (Simplex Assay, Duplex Assay, Triplex Assay, Multiplex Assay (Syndromic Testing)), Testing Location (Laboratory Based Point-of-Care Testing (POCT), At-Home Point-of-Care Testing (POCCT)), End User (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgery Centers, Elderly Care Centers and Others), Distribution Channel (Direct Tender, Retail Sales, Online Sales and Others) - Industry Trends and Forecast to 2032
Overview of U.S. Point of Care Testing Market Dynamics:
Driver
- Rising prevalence of chronic and infectious diseases increasing demand for rapid, decentralized diagnostics
Restraint
- High costs for advanced POCT devices and reagents
Opportunity
- Increasing use in drug abuse, infection disease and oncology screening, driving market diversification
Market Players:
The key players operating in the U.S. point of care testing market are:
- Danaher Corporation (U.S.)
- F. Hoffmann-La Roche Ltd (Foundation Medicine) (Switzerland / U.S.)
- Siemens Healthineers AG (Germany)
- Becton, Dickinson and Company (U.S.)
- Abbott Laboratories (U.S.)
- Agilent Technologies Inc. (U.S.)
- Abaxis, Inc. (U.S.)
- binx health, inc. (U.S.)
- bioMerieux SA (France)
- Bio-Rad Laboratories Inc. (U.S.)
- Creative Diagnostics (U.S.)
- Cardinal Health (U.S.)
- Canadian Hospital Specialties Limited (Canada)
- EKF Diagnostics Holdings plc (U.K.)
- Henry Schein Inc. (U.S.)
- Hipro Biotechnology Co., Ltd. (China)
- Medline Industries, LP (U.S.)
- Meridian Bioscience, Inc. (U.S.)
- Nipro Corporation (Japan)
- Nova Biomedical (U.S.)
- OraSure Technologies Inc. (U.S.)
- PTS Diagnostics (U.S.)
- QIAGEN (Germany)
- QuantuMDx Group Limited (U.K.)
- QuidelOrtho Corporation (U.S.)
- Radiometer Medical ApS (Denmark)
- Sanner GmbH (Germany)
- Sekisui Diagnostics (U.S.)
- Sysmex Corporation (Japan)
- Sangunia (Georgia)
- The Stevens Company Limited (Canada)
- Thermo Fisher Scientific (U.S.)
- Trimedic Inc. (Canada)
- Trinity Biotech Plc (Ireland)
TABLE OF CONTENTS
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW 19
1.4 CURRENCY AND PRICING 21
1.5 LIMITATIONS 21
1.6 MARKETS COVERED 21
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 25
2.4 DBMR TRIPOD DATA VALIDATION MODEL 26
2.5 MULTIVARIATE MODELING 30
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.7 DBMR MARKET POSITION GRID 33
2.8 VENDOR SHARE ANALYSIS 34
2.9 MARKET END USER COVERAGE GRID 36
2.10 SECONDARY SOURCES 38
2.11 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 45
4.1 PORTER'S FIVE FORCES 47
4.2 PESTEL ANALYSIS 48
4.2.1 POLITICAL FACTORS 48
4.2.2 ECONOMIC FACTORS 49
4.2.3 SOCIAL FACTORS 49
4.2.4 TECHNOLOGICAL FACTORS 50
4.2.5 ENVIRONMENTAL FACTORS 50
4.2.6 LEGAL FACTORS 51
4.3 R&D ANALYSIS 52
4.3.1 COMPARATIVE ANALYSIS 52
4.3.2 DRUG DEVELOPMENTAL LANDSCAPE 52
4.3.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES 53
4.3.4 THERAPEUTIC ASSESSMENT 53
4.3.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS 53
4.4 HEALTHCARE TARIFFS IMPACT ANALYSIS 54
4.4.1 OVERVIEW 54
4.4.2 TARIFF STRUCTURES 54
4.4.2.1 GLOBAL VS. REGIONAL TARIFF STRUCTURES 54
4.4.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 54
4.4.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS 54
4.4.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS 54
4.4.3.3 KEY TRADE AGREEMENTS AFFECTING TARIFFS 54
4.4.4 IMPACT OF TARIFFS ON PROVIDERS AND PATIENTS 55
4.4.4.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 55
4.4.4.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE 55
4.4.4.3 TARIFFS AND MEDICAL TOURISM 55
4.4.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 55
4.4.5.1 WTO REGULATIONS 55
4.4.5.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 55
4.4.5.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 55
4.4.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 56
4.4.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 56
4.5 PATENT ANALYSIS- 57
4.6 MARKETED DRUG ANALYSIS 63
4.6.1 10-YEAR MARKET FORECAST 63
4.6.2 DRUGS 63
4.6.3 BRANDED DRUGS 63
4.6.4 GENERIC DRUGS 63
4.6.5 THERAPEUTIC INDICATION 64
4.6.6 PHARMACOLOGICAL CLASS OF THE DRUG 64
4.6.7 DRUG PRIMARY INDICATION 64
4.6.8 MARKET STATUS 64
4.6.9 MEDICATION TYPE 64
4.6.10 DRUG DOSAGE FORM 64
4.6.11 DOSAGE AVAILABILITY 65
4.6.12 PACKAGING TYPE 65
4.6.13 DRUG ROUTE OF ADMINISTRATION 65
4.6.14 DOSING FREQUENCY 65
4.6.15 DRUG INSIGHT 65
4.6.16 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES 65
4.6.17 REGULATORY MILESTONE, SAFETY DATA, AND EFFICACY DATA 66
4.6.18 MARKET EXCLUSIVITY DATA 66
4.6.19 FORECAST MARKET OUTLOOK 66
4.6.20 CROSS COMPETITION 66
4.6.21 THERAPEUTIC PORTFOLIO 66
4.6.22 CURRENT DEVELOPMENT SCENARIO 66
4.7 MARKET ACCESS 67
4.7.1 10-YEAR MARKET FORECAST 67
4.7.2 CLINICAL TRIAL RECENT UPDATES 67
4.7.3 ANNUAL NEW FDA-APPROVED DRUGS 67
4.7.4 DRUG MANUFACTURER AND DEALS 67
4.7.5 MAJOR DRUG UPTAKE 68
4.7.6 CURRENT TREATMENT PRACTICES 68
4.7.7 IMPACT OF UPCOMING THERAPY 68
4.8 EPIDEMOLOGY 69
4.8.1 INCIDENCE BY GENDER: POCT-RELEVANT CONDITIONS 69
4.8.2 TREATMENT RATE: IMPACT ON POCT 69
4.8.3 MORTALITY RATE: THE NEED FOR TIMELY DIAGNOSIS 70
4.8.4 DRUG ADHERENCE AND THERAPY SWITCH: POCT'S ROLE IN MANAGEMENT 70
4.8.5 PATIENT TREATMENT SUCCESS RATES: THE POCT ADVANTAGE 70
4.9 SUPPLY CHAIN ECOSYSTEM 71
4.9.1 PROMINENT COMPANIES 71
4.9.2 KEY COMPONENTS OF THE ECOSYSTEM: 71
4.9.3 SMALL & MEDIUM SIZE COMPANIES (INNOVATORS) 72
4.9.4 END USERS 72
4.10 INNOVATION TRACKER & STRATEGIC ANALYSIS 74
4.10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS 74
4.10.1.1 JOINT VENTURES 74
4.10.1.2 MERGERS & ACQUISITIONS 74
4.10.1.3 LICENSING & PARTNERSHIPS 74
4.10.1.4 TECHNOLOGY COLLABORATIONS 75
4.10.1.5 STRATEGIC DIVESTMENTS 75
4.10.2 NUMBER OF PRODUCTS IN DEVELOPMENT 75
4.10.3 STAGE OF DEVELOPMENT 75
4.10.4 TIMELINES & MILESTONES 76
4.10.5 INNOVATION STRATEGIES & METHODOLOGIES 76
4.10.6 RISK ASSESSMENT & MITIGATION 76
4.10.7 FUTURE OUTLOOK 76
4.11 PIPELINE ANALYSIS - CANADA AND USA POINT OF CARE TESTING MARKET 77
4.11.1 CLINICAL TRIALS AND PHASE ANALYSIS 77
4.11.2 TECHNOLOGY PIPELINE 77
4.11.3 PHASE III CANDIDATES 78
4.11.4 PHASE II CANDIDATES 78
4.11.5 PHASE I CANDIDATES 78
4.11.6 OTHERS (PRE-CLINICAL AND RESEARCH) 79
4.11.7 CONCLUSION 79
5 REGULATION COVERAGE 80
6 MARKET OVERVIEW 82
6.1 DRIVERS 84
6.1.1 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES INCREASING DEMAND FOR RAPID, DECENTRALIZED DIAGNOSTICS 84
6.1.2 ADVANCED HEALTHCARE INFRASTRUCTURE AND STRONG MOBILE/WEARABLE ADOPTION IN CANADA AND THE U.S. 86
6.1.3 GROWING PATIENT PREFERENCE FOR FAST, CONVENIENT, NEAR-PATIENT TESTING OPTIONS 88
6.1.4 INCREASING GOVERNMENT INITIATIVES AND FUNDING TO SUPPORT DIGITAL HEALTH AND DECENTRALIZED DIAGNOSTICS 90
6.2 RESTRAINTS 92
6.2.1 HIGH COSTS FOR ADVANCED POCT DEVICES AND REAGENTS 92
6.2.2 VARIABILITY IN DEVICE PERFORMANCE AND QUALITY ACROSS BRANDS, COMPLICATING STANDARDIZATION AND CLINICAL ADOPTION 93
6.3 OPPORTUNITIES 95
6.3.1 INCREASING USE IN DRUG ABUSE, INFECTIOUS DISEASE, AND ONCOLOGY SCREENING, DRIVING MARKET DIVERSIFICATION 95
6.3.2 EXPANDING USE OF MOLECULAR POCT AND LATERAL FLOW IMMUNOASSAYS, INCLUDING PHARMACIES AND REMOTE/RURAL CARE 96
6.3.3 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR ENHANCED DIAGNOSTIC ACCURACY AND CLINICAL DECISION SUPPORT 97
6.4 CHALLENGES 98
6.4.1 MAINTAINING ACCURACY, RELIABILITY, AND REGULATION COMPLIANCE ACROSS DECENTRALIZED TESTING ENVIRONMENTS 98
6.4.2 ADDRESSING DATA PRIVACY AND CYBERSECURITY RISKS AS MORE POCT DEVICES CONNECT TO HEALTH NETWORKS 99
7 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY PRODUCT/DISEASE 100
7.1 OVERVIEW 101
7.2 RESPIRATORY INFECTION 108
7.2.1 SARS-COV-2 109
7.2.2 INFLUENZA A/B 109
7.2.3 RESPIRATORY SYNCYTIAL VIRUS (RSV) 109
7.2.4 BORDETELLA PERTUSSIS 109
7.2.5 OTHERS 109
?
7.3 GASTROENTERIC INFECTIONS 109
7.3.1 CLOSTRIDIOIDES DIFFICILE 110
7.3.2 NOROVIRUS 110
7.3.3 ROTAVIRUS 110
7.3.4 SALMONELLA, SHIGELLA, CAMPYLOBACTER, E. COLI (STEC) 110
7.3.5 GIARDIA 110
7.4 SEXUALLY TRANSMITTED DISEASE (STD) 111
7.5 HEPATITIS 112
7.6 BLOODSTREAM INFECTIONS (BSI) 113
7.7 BLOOD YEAST INFECTIONS (FUNGAL BSI) 114
7.8 OTHERS 115
8 CANADA AND U.S. OF CARE TESTING MARKET, BY METHOD/TECHNOLOGY 116
8.1 OVERVIEW 117
8.2 NAAT (NUCLEIC ACID AMPLIFICATION TESTS) 124
8.3 LAMP (LOOP-MEDIATED ISOTHERMAL AMPLIFICATION) 125
8.4 MICROFLUIDICS / LAB-ON-A-CHIP 125
8.5 OTHERS 125
9 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY PANEL TYPE 126
9.1 OVERVIEW 127
9.2 SIMPLEX ASSAY 134
9.3 MULTIPLEX PANEL (SYNDROMIC TESTING) 134
9.4 DUPLEX ASSAY 135
9.5 TRIPLEX ASSAY 135
10 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY TESTING LOCATION 136
10.1 OVERVIEW 137
10.2 LABORATORY BASED POINT-OF-CARE-TESTING (POCT) 144
10.3 AT-HOME POINT-OF-CARE-TESTING (POCT) 144
11 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY END USER 145
11.1 OVERVIEW 146
11.2 HOSPITALS 153
11.3 HOME CARE 153
11.4 CLINICS 153
11.5 LABORATORIES 153
11.6 AMBULATORY SURGERY CENTERS 154
11.7 ELDERLY CARE CENTERS 154
11.8 OTHERS 154
12 CANADA AND U.S. POINT OF CARE TESTING MARKET, BY DISTRIBUTION CHANNEL 155
12.1 OVERVIEW 156
12.2 DIRECT TENDER 163
12.3 RETAIL SALES 163
12.4 ONLINE SALES 163
12.5 OTHERS 163
13 CANADA AND U.S. POINT OF CARE TESTING MARKET: COMPANY LANDSCAPE 164
13.1 COMPANY SHARE ANALYSIS: U.S. 164
13.2 COMPANY SHARE ANALYSIS: CANADA 165
14 SWOT ANALYSIS 166
15 COMPANY PROFILE 167
15.1 DANAHER CORPORATION. 167
15.1.1 COMPANY SNAPSHOT 167
15.1.2 REVENUE ANALYSIS 167
15.1.3 PRODUCT PORTFOLIO 168
15.1.4 RECENT DEVELOPMENT 169
15.2 F. HOFFMANN-LA ROCHE LTD 170
15.2.1 COMPANY SNAPSHOT 170
15.2.2 RECENT FINANCIALS 170
15.2.3 PRODUCT PORTFOLIO 171
15.2.4 RECENT DEVELOPMENTS 172
15.3 SIEMENS HEALTHINEERS AG 173
15.3.1 COMPANY SNAPSHOT 173
15.3.2 RECENT FINANCIALS 173
15.3.3 PRODUCT PORTFOLIO 174
15.3.4 RECENT DEVELOPMENTS 174
15.4 BD 175
15.4.1 COMPANY SNAPSHOT 175
15.4.2 RECENT FINANCIALS 176
15.4.3 PRODUCT PORTFOLIO 176
15.4.4 RECENT DEVELOPMENTS 177
15.5 ABBOTT 178
15.5.1 COMPANY SNAPSHOT 178
15.5.2 REVENUE ANALYSIS 178
15.5.3 PRODUCT PORTFOLIO 179
15.5.4 RECENT DEVELOPMENT 179
15.6 AGILENT TECHNOLOGIES INC. 180
15.6.1 COMPANY SNAPSHOT 180
15.6.2 RECENT FINANCIALS 180
15.6.3 PRODUCT PORTFOLIO 181
15.6.4 RECENT DEVELOPMENTS 181
15.7 ABAXIS, INC. 182
15.7.1 COMPANY SNAPSHOT 182
15.7.2 PRODUCT PORTFOLIO 182
15.7.3 RECENT DEVELOPMENT 182
15.8 BINX HEALTH, INC. 183
15.8.1 COMPANY SNAPSHOT 183
15.8.2 PRODUCT PORTFOLIO 183
15.8.3 RECENT DEVELOPMENT 184
15.9 BIOMERIEUX 185
15.9.1 COMPANY SNAPSHOT 185
15.9.2 RECENT FINANCIALS 185
15.9.3 PRODUCT PORTFOLIO 186
15.9.4 RECENT DEVELOPMENT 186
15.10 BIO-RAD LABORATORIES, INC. 187
15.10.1 COMPANY SNAPSHOT 187
15.10.2 REVENUE ANALYSIS 187
15.10.3 PRODUCT PORTFOLIO 188
15.10.4 RECENT DEVELOPMENT 188
15.11 CREATIVE DIAGNOSTICS 189
15.11.1 COMPANY SNAPSHOT 189
15.11.2 PRODUCT PORTFOLIO 189
15.11.3 RECENT DEVELOPMENT 189
15.12 CARDINAL HEALTH 190
15.12.1 COMPANY SNAPSHOT 190
15.12.2 REVENUE ANALYSIS 190
15.12.3 PRODUCT PORTFOLIO 191
15.12.4 RECENT DEVELOPMENT 191
15.13 CANADIAN HOSPITAL SPECIALTIES LIMITED 192
15.13.1 COMPANY SNAPSHOT 192
15.13.2 PRODUCT PORTFOLIO 192
15.13.3 RECENT DEVELOPMENT 192
?
15.14 EKF DIAGNOSTICS HOLDINGS PLC. 193
15.14.1 COMPANY SNAPSHOT 193
15.14.2 REVENUE ANALYSIS 193
15.14.3 PRODUCT PORTFOLIO 194
15.14.4 RECENT DEVELOPMENT 194
15.15 HENRY SCHEIN, INC. 195
15.15.1 COMPANY SNAPSHOT 195
15.15.2 REVENUE ANALYSIS 195
15.15.3 PRODUCT PORTFOLIO 196
15.15.4 RECENT DEVELOPMENT 197
15.16 HIPRO BIOTECHNOLOGY CO.,LTD. 198
15.16.1 COMPANY SNAPSHOT 198
15.16.2 PRODUCT PORTFOLIO 198
15.16.3 RECENT DEVELOPMENTS 198
15.17 MEDLINE INDUSTRIES, LP 199
15.17.1 COMPANY SNAPSHOT 199
15.17.2 PRODUCT PORTFOLIO 199
15.17.3 RECENT DEVELOPMENT 199
15.18 MERIDIAN BIOSCIENCE, INC 200
15.18.1 COMPANY SNAPSHOT 200
15.18.2 PRODUCT PORTFOLIO 200
15.18.3 RECENT DEVELOPMENT 201
15.19 NIPRO 202
15.19.1 COMPANY SNAPSHOT 202
15.19.2 RECENT FINANCIALS 202
15.19.3 PRODUCT PORTFOLIO 203
15.19.4 RECENT DEVELOPMENTS 203
15.20 NOVA BIOMEDICAL 204
15.20.1 COMPANY SNAPSHOT 204
15.20.2 PRODUCT PORTFOLIO 204
15.20.3 RECENT DEVELOPMENT 205
15.21 ORASURE TECHNOLOGIES INC 206
15.21.1 COMPANY SNAPSHOT 206
15.21.2 REVENUE ANALYSIS 206
15.21.3 PRODUCT PORTFOLIO 207
15.21.4 RECENT DEVELOPMENT 208
15.22 PTS DIAGNOSTICS 209
15.22.1 COMPANY SNAPSHOT 209
15.22.2 PRODUCT PORTFOLIO 209
15.22.3 RECENT DEVELOPMENT 209
15.23 QIAGEN 210
15.23.1 COMPANY SNAPSHOT 210
15.23.2 REVENUE ANALYSIS 210
15.23.3 PRODUCT PORTFOLIO 211
15.23.4 RECENT DEVELOPMENT 212
15.24 QUANTUMDX GROUP LTD. 213
15.24.1 COMPANY SNAPSHOT 213
15.24.2 PRODUCT PORTFOLIO 213
15.24.3 RECENT DEVELOPMENT 213
15.25 QUIDELORTHO CORPORATION. 214
15.25.1 COMPANY SNAPSHOT 214
15.25.2 REVENUE ANALYSIS 214
15.25.3 PRODUCT PORTFOLIO 215
15.25.4 RECENT DEVELOPMENTS 215
15.26 RADIOMETER MEDICAL APS 216
15.26.1 COMPANY SNAPSHOT 216
15.26.2 PRODUCT PORTFOLIO 216
15.26.3 RECENT UPDATES 217
15.27 SANNER 218
15.27.1 COMPANY SNAPSHOT 218
15.27.2 PRODUCT PORTFOLIO 218
15.27.3 RECENT DEVELOPMENT 218
15.28 SEKISUI DIAGNOSTICS 219
15.28.1 COMPANY SNAPSHOT 219
15.28.2 PRODUCT PORTFOLIO 219
15.28.3 RECENT DEVELOPMENT 220
15.29 SYSMEX CORPORATION 221
15.29.1 COMPANY SNAPSHOT 221
15.29.2 REVENUE ANALYSIS 221
15.29.3 PRODUCT PORTFOLIO 222
15.29.4 RECENT DEVELOPMENT 222
15.30 SANGUNIA 223
15.30.1 COMPANY SNAPSHOT 223
15.30.2 PRODUCT PORTFOLIO 223
15.30.3 RECENT DEVELOPMENTS 223
15.31 THE STEVENS COMPANY LIMITED 224
15.31.1 COMPANY SNAPSHOT 224
15.31.2 PRODUCT PORTFOLIO 224
15.31.3 RECENT DEVELOPMENT 224
?
15.32 THERMO FISHER SCIENTIFIC INC. 225
15.32.1 COMPANY SNAPSHOT 225
15.32.2 REVENUE ANALYSIS 225
15.32.3 PRODUCT PORTFOLIO 226
15.32.4 RECENT DEVELOPMENT 226
15.33 TRIMEDIC INC 227
15.33.1 COMPANY SNAPSHOT 227
15.33.2 PRODUCT PORTFOLIO 227
15.33.3 RECENT DEVELOPMENT 227
15.34 TRINITY BIOTECH 228
15.34.1 COMPANY SNAPSHOT 228
15.34.2 REVENUE ANALYSIS 228
15.34.3 PRODUCT PORTFOLIO 229
15.34.4 RECENT DEVELOPMENT 229
16 QUESTIONNAIRE 230
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security